Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: A prospective cohort study

International Journal of Obstetric Anesthesia

Volumn 22, Issue 4, 2013, Pages 280-288

  Hiscock, R J ^a   Casey, E ^a   Simmons, S W ^a,b   Walker, S P ^a   Newell, P A ^a  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anti Xa levels; Caesarean; Enoxaparin; Thromboprophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; TINZAPARIN;

ADULT; ARTICLE; BLEEDING; CESAREAN SECTION; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RISK FACTOR; TERTIARY HEALTH CARE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTI-XA LEVELS; CAESAREAN; ENOXAPARIN; THROMBOPROPHYLAXIS;

ADULT; ANTICOAGULANTS; BODY MASS INDEX; CESAREAN SECTION; COHORT STUDIES; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; PREGNANCY; PROSPECTIVE STUDIES; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84886091821     PISSN: 0959289X     EISSN: 15323374     Source Type: Journal    
DOI: 10.1016/j.ijoa.2013.05.008     Document Type: Article

References (27)

1. Centre for Maternal and Child Enquiries (CMACE) Saving mothers' lives: reviewing maternal deaths to make motherhood safer 2006-2008. The eight report of the confidential enquiries into maternal deaths in the United Kingdom BJOG 118 Suppl. 1 2011 1 203
2. E. Pomp, A. Lenselink, F. Rosendaal, and C. Doggen Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study J Thromb Haemost 6 2008 632 637
3. S. Bates, I. Greer, S. Middeldorp, D. Veenstra, A. Prabulos, and P. Vandvik VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e691 e736S
4. S. Clark, M. Belfort, G. Dildy, M. Herbst, J. Meyers, and G. Hankins Maternal death in the 21st century: causes, prevention, and relationship to cesarean delivery Am J Obstet Gynecol 199 2008 36.e1 36.e5
5. E. Fyfe, J. Thompson, N. Anderson, K. Groom, and L. McGowan Maternal obesity and postpartum haemorrhage after vaginal and caesarean delivery among nulliparous women at term: a retrospective cohort study BMC Pregnancy Childbirth 12 2012 112 114
6. W. Sia, R. Powrie, and A. Cooper The incidence of deep vein thrombosis in women undergoing cesarean delivery Thromb Res 123 2009 550 555
7. J. Morris, C. Algert, and C. Roberts Incidence and risk factors for pulmonary embolism in the postpartum period J Thromb Haemost 8 2010 998 1003
8. Royal College of Obstetricians and Gynaecologists. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline No. 37a. London: RCOG, 2009. http://www.rcog.org.uk/files/rcog-corp/ GTG37aReducingRiskThrombosis.pdf [accessed May 2013].
9. C. McLintock, T. Brighton, and S. Chunilal Recommendations for the prevention of pregnancy-associated venous thromboembolism Aust N Z J Obstet Gynaecol 52 2012 3 13
10. A. Duhl, M. Paidas, and H. Serdar Antithrombotic therapy and pregnancy: concensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes Am J Obstet Gynecol 457 2007 e1 e21
11. N. Birri, D. Baumgartner, and T. Conte Stability of low molecular weight heparin anti-factor Xa activity in citrated whole blood and plasma Br J Haematol 155 2011 629 631
12. L. Desjardins, L. Bara, and F. Boutitie Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX Study Arch Pathol Lab Med 128 2004 519 526
13. C. Lebaudy, J. Hulot, and Z. Amoura Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy Clin Pharmacol Ther 84 2008 370 377
14. J. Gibson, K. Ekevall, I. Walker, and I. Greer Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin BJOG 105 1998 795 797
15. S. Stock, M. Walker, B. Edelshain, L. Horn, J. Norman, and F. Denison Fixed dosing regimes of enoxaparin for thromboprophylaxis do not reliably achieve target anti-Xa levels in women of normal weight during pregnancy Eur J Obstet Gynecol Reprod Biol 158 2011 112 113
16. S. Frederiksen, J. Hedenbro, and L. Norgren Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients Br J Surg 90 2003 547 548
17. J. Wilson, K. Wilbur, E. Burton, and D. Anderson Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular weight heparin for treatment of venous thromboembolism Haemostasis 31 2001 42 48
18. M. Samama, C. Verhille, and L. Darchy Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery Thromb Haemost 73 1995 977
19. Rasmussen MS, Jørgensen LN, Wille-Jørgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Sys Rev 2009; CD004318. DOI: http://dx.doi.org/10. 1002/14651858.CD004318.pub2.
20. D. Bergqvist, G. Lowe, and A. Berstad Prevention of venous thromboembolism after surgery: a review of enoxaparin Br J Surg 79 1992 495 498
21. M. Samama, A. Cohen, and J. Darmon A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients N Engl J Med 341 1999 793 800
22. E. Antman, and R. Handin Low-molecular-weight heparins. An intriguing new twist with profound implication Circulation 98 1998 287 289
23. R. Adams, and R. Bird Review article: Coagulation cascade and therapeutics update: relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants Nephrology 14 2009 462 470
24. F. Depasse, M. Gonzalez de Suso, I. Lagoutte, J. Fontcuberta, M. Borrell, and M. Samama Comparative study of the pharmacokinetic profiles of two LMWHs - bemiparin (3500IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) - administered subcutaneously to healthy male volunteers Thromb Res 109 2003 109 117
25. S. Ismail, L. Norris, S. Muttukrishna, and J. Higgins Thrombin generation post elective caesarean section: effect of low molecular weight heparin Thromb Res 130 2012 799 803
26. B. Bendz, T. Andersen, and P. Sandset Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins Blood Coagul Fibrinolysis 11 2000 343 348
27. M. Rondina, M. Wheeler, G. Rodgers, L. Draper, and R. Pendleton Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients Thromb Res 125 2010 220 223